On September 20, 2023, it was reported that Harbor Capital Advisors Inc. had acquired a new stake in Twist Bioscience Co. The investment firm purchased 24,835 shares of the company’s stock, valued at approximately $508,000. This significant purchase highlights the growing interest and potential in Twist Bioscience Corporation.
Twist Bioscience Corporation is a pioneering synthetic biology company that specializes in the manufacturing and sale of synthetic DNA-based products. Their unique DNA synthesis platform utilizes silicon chips to write DNA, enabling efficient and precise production of synthetic DNA. This innovative approach has revolutionized various industries reliant on genetic engineering and biotechnology.
One of the key offerings from Twist Bioscience is its wide range of synthetic DNA-based products. These include synthetic genes, crucial tools for sample preparation, antibody libraries used in drug discovery and development processes, and even utilizing DNA as a digital data storage medium. By leveraging their advanced technology and expertise in DNA synthesis, Twist Bioscience has positioned itself as a leading player in the field.
Harbor Capital Advisors Inc.’s decision to invest in Twist Bioscience reflects their confidence in the company’s future prospects. As an investment firm known for making strategic investment choices, their acquisition of shares indicates their belief in the long-term growth potential of Twist Bioscience.
This latest development comes at an opportune time for Twist Bioscience as they continue to make advancements in synthetic biology. With increasing demand for genetic engineering solutions across various industries such as healthcare, agriculture, and industrial manufacturing, the market potential for synthetic DNA-based products is vast. By capitalizing on this growing demand through their cutting-edge technology and product offerings, Twist Bioscience is well-positioned for success.
In conclusion, Harbor Capital Advisors Inc.’s recent acquisition of a stake in Twist Bioscience Co., along with their substantial investment amounting to $508,000 further solidifies this synthetic biology company’s prominence in the market. As the demand for synthetic DNA-based products continues to soar, Twist Bioscience’s innovative approach and reliable solutions position them as a prominent player within the industry. The future looks promising for Twist Bioscience Corporation, and investors like Harbor Capital Advisors Inc. recognize their potential for long-term growth and success.
[bs_slider_forecast ticker=”NGVT”]
Institutional Investors and Hedge Funds Increase Holdings of Twist Bioscience, Indicating Promising Growth Potential in the Biotechnology Sector
Institutional investors and hedge funds have recently made changes to their holdings of Twist Bioscience, a leading biotechnology company. Among these investors, ARK Investment Management LLC increased its stake in the company by 7.1% in the first quarter, now owning 7,179,112 shares valued at $108,261,000. BlackRock Inc. also raised its stake in Twist Bioscience by 13.2% during the same period, currently owning 6,213,441 shares worth $93,699,000. State Street Corp saw a 19.2% increase in its stake with 5,275,841 shares valued at $79,560,000. Capital World Investors also raised its holding by 6%, now owning 4,795,848 shares worth $236,819,000. Lastly, Vanguard Group Inc. increased its stake by 10.8%, now possessing 4,791,074 shares with a value of $236,584.
Several research firms have recently issued reports on Twist Bioscience’s performance as well. Barclays has raised its price objective for TWST stock from $20 to $26 and provided an “overweight” rating for the stock in a report on August 7th. Similarly Robert W. Baird has increased the price objective of Twist Bioscience from $18 to $27 on the same day.
As for TWST’s recent stock performance; it opened at $20.33 on Wednesday and had a 12-month low of $11.46 and high of $40.50.The stockÂ’s moving averages include a 50-day average of $22.50 and a 200-day average of $18.10.
The latest earnings results from Twist Bioscience were disclosed on August 4th with an earnings per share (EPS) of ($1.01) for the quarter which surpassed consensus expectations of ($1.14) by $0.13. The company’s revenue for the quarter was $63.80 million, higher than analysts’ projections of $60.62 million. Despite this positive report, Twist Bioscience had a negative return on equity of 29.09% and a negative net margin of 88.97%. However, the business’s revenue showed growth of 13.7% compared to the same quarter in the previous year when it posted an EPS of ($1.08). Research analysts predict that Twist Bioscience Co.’s earnings per share for the current year will be -3.73.
Overall, Twist Bioscience has shown promising performance with increased stake by institutional investors and hedge funds along with positive earnings results that exceeded expectations in the second quarter, indicating potential for future growth in the biotechnology sector.
Please note that all information provided is based on data available as of September 20, 2023 and may be subject to change or further updates from relevant sources.
